The phrase refers to a set of directives issued by the previous presidential administration aimed at lowering the cost of pharmaceuticals for consumers in the United States. These directives typically involved policy changes affecting Medicare, rebates paid to pharmacy benefit managers, and the importation of drugs from other countries. For example, one component might have targeted the practice of pharmaceutical companies providing rebates to insurance companies and pharmacy benefit managers, with the goal of ensuring those savings were passed on to patients at the pharmacy counter.
The significance of these actions stems from concerns regarding rising healthcare expenses and the affordability of medications. Proponents suggested these measures could reduce out-of-pocket costs for individuals, improve access to essential treatments, and foster greater transparency within the pharmaceutical industry. Historically, the cost of prescription drugs has been a persistent political and economic challenge, with various administrations attempting different strategies to address the issue, often facing resistance from pharmaceutical companies and navigating complex regulatory frameworks.
